CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference
29 Februar 2024 - 10:01PM
CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage
biotechnology company positioned to advance next generation,
potentially curative cell therapies for cancer patients, today
announced that the company will participate in the 44th Annual
Cowen Healthcare Conference, taking place March 4-6, 2024, in
Boston, Massachusetts.
Gina Chapman, President and Chief Executive
Officer, is scheduled to participate in a cell therapy corporate
panel discussion on Wednesday, March 6, at 9:10 a.m. EST.
A live webcast of the panel discussion will be
accessible through the Investors section of CARGO’s website under
News & Events. A replay of the webcast will be available after
the conclusion of the live presentation for 30 days.
About CARGO
CARGO Therapeutics, Inc. is a clinical-stage
biotechnology company positioned to advance next generation,
potentially curative cell therapies for cancer patients. CARGO’s
programs, platform technologies, and manufacturing strategy are
designed to directly address the limitations of approved cell
therapies, including limited durability of effect, safety concerns
and unreliable supply. CARGO is currently evaluating its lead
program, CRG-022, an autologous CD22 chimeric antigen receptor
(CAR) T-cell therapy candidate, in a potentially pivotal Phase 2
clinical trial in patients with large B-cell lymphoma (LBCL) whose
disease relapsed or was refractory (R/R) to CD19 CAR T-cell
therapy. CARGO also plans to evaluate CRG-022 in patients at
earlier stages of disease, including LBCL and other hematologic
malignancies. Beyond its lead program, CARGO is leveraging its
proprietary cell engineering platform technologies to develop a
pipeline of programs that incorporate multiple transgene
therapeutic “cargo” designed to enhance CAR T-cell persistence and
trafficking to tumor lesions, as well as to help safeguard against
tumor resistance and T-cell exhaustion. CARGO’s founders are
pioneers and world-class experts in CAR T-cell therapy, and CARGO’s
team has significant experience and success developing,
manufacturing, launching and commercializing oncology and cell
therapy products.
Media Contact:Maura
Gavaghanmaura@redhousecomms.com
Investor Contact:Laurence
Wattslaurence@gilmartinir.com
CARGO Therapeutics (NASDAQ:CRGX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
CARGO Therapeutics (NASDAQ:CRGX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024